Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) - 09/08/11
, John H. Ip, MD, FACC a, Brian Olshansky, MD, FACC b, Anne S. Hellkamp, MS c, Jill Anderson, RN d, Jeanne E. Poole, MD, FACC d, Daniel B. Mark, MD, MPH, FACC c, Kerry L. Lee, PhD c, Gust H. Bardy, MD, FACC dfor the SCD-HeFT Investigators
Riassunto |
Background |
Recent observations suggest statin treatment may be associated with lower mortality in heart failure (HF). The SCD-HeFT was a study of 2521 functional class II and III HF patients with left ventricular ejection fractions ≤35% and ischemic and nonischemic cardiomyopathy followed up for a median of 45.5 months. The study length, size, and degree of background HF, including the use of implantable defibrillator therapy, provide a unique opportunity to evaluate the impact of statin use in HF with mechanistic insights from subgroup analyses.
Methods and Results |
Statin use was reported in 965 (38%) of 2521 patients at baseline and 1187 (47%) at last follow-up. The relationships between statin use, randomization arm, disease category, and functional class and all cause mortality were assessed. Statin use was studied as a time-dependent covariate in a multivariable Cox proportional hazards model, adjusted for imbalances between statin and no-statin groups. Mortality risk was significantly lower in those taking a statin (HR [95% CI], 0.70 [0.58-0.83]). Mortality risk was lower with statin use in all prespecified subgroups: ischemic cardiomyopathy (0.69 [0.56-0.86]), nonischemic cardiomyopathy (0.67 [0.47-0.96]), implantable cardioverter defibrillator (ICD) (0.66 [0.46-0.95], non-ICD (0.71 [0.57-0.87]), New York Heart Association II (0.62 [0.48-0.79]), and New York Heart Association III (0.79 [0.61-1.03]).
Conclusions |
Statin use is associated with reduced all-cause mortality in HF patients. Statins appear to benefit patients with nonischemic and ischemic cardiomyopathy similarly. Statin benefits are similar in ICD and non-ICD patients.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| SCD-HeFT was sponsored by grants (UO1 HL55766, UO1 HL55297, and UO1 HL 55496) from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethesda, MD. Subsidiary research funding was provided by Medtronic, Inc, Minneapolis, MN, and Wyeth-Ayerst Laboratories, Philadelphia, PA. |
Vol 153 - N° 4
P. 573-578 - aprile 2007 Ritorno al numero
Articolo precedente
- Exercise capacity in atrial fibrillation: A substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T)
- J. Edwin Atwood, Jonathan N. Myers, X. Charlene Tang, Domenic J. Reda, Steven N. Singh, Bramah N. Singh
- The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy–facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis of randomized clinical trials
- Mohamad C.N. Sinno, Sanjaya Khanal, Mouaz H. Al-Mallah, Muhammad Arida, W. Douglas Weaver
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?